New drug cocktail shows promise in shrinking head and neck tumors before surgery
NCT ID NCT04080804
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether giving immune-boosting drugs before surgery can help shrink head and neck cancer tumors. About 80 adults with advanced but removable cancer will receive either nivolumab alone or combined with relatlimab or ipilimumab. Researchers will monitor side effects and measure how much the tumors shrink, aiming to improve treatment outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a One-Two punch of radiation and immunotherapy shrink head and neck tumors before surgery?
- Can an immunotherapy combo shrink head and neck tumors before surgery?
- Vaccine trains immune system to fight HPV-Positive head and neck tumors
- New scan could sharpen detection of head and neck cancers
- New cocktail aims to shrink head and neck tumors before surgery
- New scan spots hidden cancer spread before surgery